Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Am J Gastroenterol

Retrieve available abstracts of 196 articles:
HTML format



Single Articles


    November 2022
  1. VARMA A, Weinstein J, Seabury J, Rosero S, et al
    Patient-Reported Impact of Symptoms in Crohn's Disease.
    Am J Gastroenterol. 2022 Nov 15. doi: 10.14309/ajg.0000000000001954.
    PubMed     Abstract available


  2. BIRCH RJ, Burr N, Subramanian V, Tiernan JP, et al
    Inflammatory Bowel Disease-Associated Colorectal Cancer Epidemiology and Outcomes: An English Population-Based Study.
    Am J Gastroenterol. 2022;117:1858-1870.
    PubMed     Abstract available


  3. DUNLEAVY K, Fogwe D, Forde G, Ho M, et al
    A Rare Complication: Postoperative Pyoderma Gangrenosum in Segmental Colitis Associated With Diverticulosis.
    Am J Gastroenterol. 2022;117:1734.
    PubMed    


  4. CHENG D, Kochar B, Cai T, Ritchie CS, et al
    Comorbidity Influences the Comparative Safety of Biologic Therapy in Older Adults With Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2022;117:1845-1850.
    PubMed     Abstract available


    October 2022
  5. BERNSTEIN CN, Fisk JD, Walld R, Bolton JM, et al
    Use of Benzodiazepines and Z-Drugs in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2022 Oct 27. pii: 00000434-990000000-00474.
    PubMed     Abstract available


  6. FAIRBRASS KM, Guthrie EA, Black CJ, Selinger CP, et al
    Characteristics and Impact of Anxiety and Depression Trajectories in Inflammatory Bowel Disease.: Anxiety and Depression Trajectories in IBD.
    Am J Gastroenterol. 2022 Oct 12. pii: 00000434-990000000-00552.
    PubMed     Abstract available


  7. EGBERG MD, Zhang X, Smitherman AB, Kappelman MD, et al
    LOW RISK OF LYMPHOMA IN PEDIATRIC PATIENTS TREATED FOR INFLAMMATORY BOWEL DISEASE.
    Am J Gastroenterol. 2022 Oct 10. pii: 00000434-990000000-00543.
    PubMed     Abstract available


  8. DONG J, Ladonne M, Feuerstein JD
    Medicare Patients Face High Out-of-Pocket Costs for Specialty Inflammatory Bowel Disease Medications.
    Am J Gastroenterol. 2022 Oct 10. pii: 00000434-990000000-00549.
    PubMed     Abstract available


  9. INAMDAR S
    Continuing Medical Education Questions: October 2022.
    Am J Gastroenterol. 2022;117:1564.
    PubMed     Abstract available


  10. SHMIDT E, Dubinsky MC
    Inflammatory Bowel Disease and Pregnancy.
    Am J Gastroenterol. 2022;117.
    PubMed    


  11. GU P, Luo J, Kim J, Paul P, et al
    Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
    Am J Gastroenterol. 2022;117:1639-1647.
    PubMed     Abstract available


    September 2022
  12. KASTL A, Weaver KN, Zhang X, Strople JA, et al
    Humoral Immune Response and Safety of SARS-CoV-2 Vaccination in Pediatric Inflammatory Bowel Disease.
    Am J Gastroenterol. 2022 Sep 16. pii: 00000434-990000000-00507.
    PubMed     Abstract available


  13. GUPTA A, Kizza JF, Ananthakrishnan AN
    Histologic activity in an endoscopically normal appearing pouch predicts future risk of pouchitis in patients with ulcerative colitis.
    Am J Gastroenterol. 2022 Sep 16. pii: 00000434-990000000-00511.
    PubMed     Abstract available


  14. DULANEY DT
    Continuing Medical Education Questions: September 2022.
    Am J Gastroenterol. 2022;117:1407.
    PubMed     Abstract available


  15. BOSCHETTI G, Nachury M, Laharie D, Roblin X, et al
    Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAID.
    Am J Gastroenterol. 2022;117:1482-1490.
    PubMed     Abstract available


    August 2022
  16. DANESE S, Ferrante M, Feagan BG, Peyrin-Biroulet L, et al
    Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial.
    Am J Gastroenterol. 2022 Aug 23. pii: 00000434-990000000-00486.
    PubMed     Abstract available


  17. COHEN-MEKELBURG S, Van T, Wallace B, Berinstein J, et al
    The association between non-steroidal anti-inflammatory drug use and inflammatory bowel disease exacerbations: a true association or residual bias?
    Am J Gastroenterol. 2022 Aug 12. pii: 00000434-990000000-00457.
    PubMed     Abstract available


  18. AGRAWAL M, Allin KH, Iversen AT, Mehandru S, et al
    Early life mebendazole exposure increases the risk of adult-onset ulcerative colitis: a population-based cohort study.
    Am J Gastroenterol. 2022 Aug 12. pii: 00000434-990000000-00466.
    PubMed     Abstract available


  19. VAN DEEN WK, Simpson M, Dupuy TP, Khalil C, et al
    Social Media for the Dissemination of Educational Videos About Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2022;117:1320-1323.
    PubMed     Abstract available


  20. ONALI S, Pugliese D, Caprioli FA, Orlando A, et al
    An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors.
    Am J Gastroenterol. 2022;117:1279-1287.
    PubMed     Abstract available


    July 2022
  21. BESSISSOW T, Kron CM, Marcus V, Lemieux C, et al
    Impact of Endoscopic and Histologic Activity on Disease Relapse in Ulcerative Colitis.
    Am J Gastroenterol. 2022 Jul 21. pii: 00000434-990000000-00439.
    PubMed     Abstract available


  22. LO B, Liu Z, Bendtsen F, Igel C, et al
    High accuracy in classifying endoscopic severity in ulcerative colitis using convolutional neural network.
    Am J Gastroenterol. 2022 Jul 15. pii: 00000434-990000000-00434.
    PubMed     Abstract available


  23. ISAACS K, Kane S
    Doctor, What Is the Best Crohn's Therapy?
    Am J Gastroenterol. 2022;117:1041-1043.
    PubMed     Abstract available


  24. JAIN A, Bricker J, Kappelman MD, Dotson JL, et al
    Overweight and Obese Status Is Not Associated With Disease Activity for Children and Adolescents With Newly Diagnosed Inflammatory Bowel Disease.
    Am J Gastroenterol. 2022;117:1146-1153.
    PubMed     Abstract available


  25. NARULA N, Wong ECL, Dulai PS, Marshall JK, et al
    Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease.
    Am J Gastroenterol. 2022;117:1106-1117.
    PubMed     Abstract available


    June 2022
  26. ALMARIO CV, van Deen WK, Chen M, Gale R, et al
    Interactive Inflammatory Bowel Disease Biologics Decision Aid Does Not Improve Patient Outcomes Over Static Education: Results from a Randomized Trial.
    Am J Gastroenterol. 2022 Jun 10. pii: 00000434-990000000-00406.
    PubMed     Abstract available


    May 2022
  27. MARILD K, Soderling J, Lebwohl B, Green PH, et al
    ASSOCIATION OF CELIAC DISEASE AND INFLAMMATORY BOWEL DISEASE: A NATIONWIDE REGISTER-BASED COHORT STUDY.
    Am J Gastroenterol. 2022 May 25. pii: 00000434-990000000-00380.
    PubMed     Abstract available


    April 2022
  28. KAPLAN HC, Opipari-Arrigan L, Yang J, Schmid CH, et al
    Personalized Research on Diet in Ulcerative Colitis and Crohn's Disease (PRODUCE): A Series of N-of-1 Diet Trials.
    Am J Gastroenterol. 2022 Apr 20. pii: 00000434-990000000-00348.
    PubMed     Abstract available


  29. LUTZ M, Hayney MS, Caldera F
    We should not forget about patients with inflammatory bowel disease who received a COVID-19 viral vector vaccine.
    Am J Gastroenterol. 2022 Apr 15. pii: 00000434-990000000-00337.
    PubMed    


  30. DULAI PS, Rai V, Raffals LE, Lukin D, et al
    Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel.
    Am J Gastroenterol. 2022 Apr 13. pii: 00000434-990000000-00329.
    PubMed    


  31. SASSINE S, Djani L, Cambron-Asselin C, Savoie M, et al
    Risk Factors of Clinical Relapses in Pediatric Luminal Crohn's Disease: A Retrospective Cohort Study.
    Am J Gastroenterol. 2022;117:637-646.
    PubMed     Abstract available


    March 2022
  32. ROLAK S, Caldera F
    The current knowns and unknowns of COVID-19 vaccine induced immunity in patients with inflammatory bowel disease.
    Am J Gastroenterol. 2022 Mar 15. pii: 00000434-990000000-00282.
    PubMed    


  33. WINTER RW, Friedman S, Nielsen J, Kjeldsen J, et al
    Infliximab Is Not Associated With a General Long-Term Weight Gain in Patients With Inflammatory Bowel Disease: A Nationwide Study.
    Am J Gastroenterol. 2022 Mar 14. pii: 00000434-990000000-00278.
    PubMed     Abstract available


  34. KAPPELMAN MD, Weaver KN, Zhang X, Dai X, et al
    Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2022;117:462-469.
    PubMed     Abstract available


    February 2022
  35. SNINSKY JA, Barnes EL, Zhang X, Long MD, et al
    Urgency and its association with quality of life and clinical outcomes in ulcerative colitis patients.
    Am J Gastroenterol. 2022 Feb 15. pii: 00000434-990000000-00253.
    PubMed     Abstract available


    January 2022
  36. TSIPOTIS E, Frey S, Connolly C, Werbel WA, et al
    Antibody Response Three Months after Two-Dose SARS-CoV-2 mRNA Vaccination in patients with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2022 Jan 29. pii: 00000434-990000000-00231.
    PubMed     Abstract available


  37. HAMADA K, Mankawa N, Yamamoto S
    May-Thurner syndrome in a patient with ulcerative colitis complicated by coronavirus disease 2019.
    Am J Gastroenterol. 2022 Jan 29. pii: 00000434-990000000-00233.
    PubMed    


  38. GARRIDO I, Lopes S, Andrade P, Real AC, et al
    Immune Response Induced by SARS-CoV-2 Vaccines in Patients With Inflammatory Bowel Disease Under Biologic Therapy.
    Am J Gastroenterol. 2022 Jan 24. pii: 00000434-990000000-00217.
    PubMed    


    December 2021
  39. MOLLY S, Margaret M, Erin F
    P076 The Role of Dual Biologic Therapy in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed    


  40. JARED S, Edward B, Xian Z, Millie L, et al
    P075 Urgency and its Association with Quality of Life and Clinical Outcomes in Ulcerative Colitis Patients.
    Am J Gastroenterol. 2021;116.
    PubMed    


  41. RAHUL D, Jennifer M, Hannah G, Jessica A, et al
    P074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naive Patients With Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  42. BENJAMIN S, Kristine P, Kevin T, James M, et al
    P072 Non-invasive Vagal Nerve Stimulation to Treat Crohn Disease and Ulcerative Colitis in Children and Young Adults: A Proof-of-Concept Clinical Trial.
    Am J Gastroenterol. 2021;116.
    PubMed    


  43. JOSE RL, Jesus LG, Tomas CE, Korely TF, et al
    P063 Prevalence in the Use of Complementary/Alternative Medicine in Patients With Inflammatory Bowel Disease from Centro Medico Nacional 20 de Noviembre.
    Am J Gastroenterol. 2021;116.
    PubMed    


  44. KORELY TF, Jesus LG, Tomas CE, Rebeca PC, et al
    P061 Impact of Inflammatory Bowel Disease on sleep quality in a Mexican population attended in a referral center.
    Am J Gastroenterol. 2021;116.
    PubMed    


  45. VIVIANA PI, Jaiber G, Cristian F, Diego J, et al
    P060 Screening Criteria of Inflammatory Bowel Disease: Application in Colombian Patients With Spondyloarthritis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  46. JULTON TC, Lauren S, Mouhammed S, Adil M, et al
    P058 Impact of Inflammatory Bowel Disease Treatment and Risk of Covid-19 Infection after Full Immunization: A Nationwide Analysis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  47. CARLOS PA, Tomas CE, Jesus LG, Korely TF, et al
    P057 How Distance Between Residence and Treatment Center Impact the Outcome of Patients With Inflammatory Bowel Disease at CMN 20.
    Am J Gastroenterol. 2021;116.
    PubMed    


  48. VIVIANA PI, Juan FO, Pablo G, Consuelo RS, et al
    P056 Real life experience with the use of tofacitinib in ulcerative colitis in Colombia: case series.
    Am J Gastroenterol. 2021;116.
    PubMed    


  49. SANG TC, Sarah A, Yousef E, Joshua T, et al
    P055 Sociodemographic Differences in Fecal Enteropathogen Testing Patterns in Adults Hospitalized for Inflammatory Bowel Disease Flares.
    Am J Gastroenterol. 2021;116.
    PubMed    


  50. MIKAELL F, Ligia S, Adriana A, Roberto KJ, et al
    P052 National Registration of Patients With Inflammatory Bowel Disease in Brazil on Behalf of GEDIIB.
    Am J Gastroenterol. 2021;116.
    PubMed    


  51. MARTA F, Tiago LC, Vitor MS, Catia A, et al
    P051 Identifying High-Risk Patients With Acute Severe Ulcerative Colitis: Is the ACE Index Useful?
    Am J Gastroenterol. 2021;116.
    PubMed    


  52. VIVIANA PI, Katherin C, Julio A, Maria B, et al
    P050 Oral Inflammatory Changes Associated With Inflammatory Bowel Disease in Spondyloarthritis Associated With Early Endoscopic Findings.
    Am J Gastroenterol. 2021;116.
    PubMed    


  53. DANIEL S, Marina L, Ana Carolina O, Rodrigo B, et al
    P049 Investigation of Liver Diseases by Ultrasound in Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed    


  54. MARINA L, Daniel S, Ana Carolina O, Rodrigo B, et al
    P045 Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD) in a Brazilian public healthcare clinic.
    Am J Gastroenterol. 2021;116.
    PubMed    


  55. QIAN C, Myrlene S, Nurgul B, Lilla DS, et al
    P043 Resource Utilization and Productivity Loss among Patients with Inflammatory Bowel Disease in Sweden: A Longitudinal Nationwide Population-based Study.
    Am J Gastroenterol. 2021;116.
    PubMed    


  56. MILLIE L, Raymond C, Jonathan C, Marc P, et al
    P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  57. JEAN-FREDERIC C, Geert D, Peter I, AnnKatrin P, et al
    P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial.
    Am J Gastroenterol. 2021;116.
    PubMed    


  58. DAVID H, Millie L, Douglas W, Stephen H, et al
    P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study.
    Am J Gastroenterol. 2021;116.
    PubMed    


  59. BRUCE S, Marc P, Michael S, AnnKatrin P, et al
    P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.
    Am J Gastroenterol. 2021;116.
    PubMed    


  60. DAVID R, Remo P, Alison PB, Cem K, et al
    P028 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Patient and Healthcare Professional Perspectives on Experience of Ulcerative Colitis Symptoms.
    Am J Gastroenterol. 2021;116.
    PubMed    


  61. APAAR D, Khushboo G, Jayesh R, Shesh R, et al
    P027 Brain Fog in Patients With Inflammatory Bowel Disease, and Association With Use of Probiotics.
    Am J Gastroenterol. 2021;116.
    PubMed    


  62. ADAM S, Nicole L, Heba I, Harini N, et al
    P026 Inflammatory Bowel Disease (IBD) Related Outcomes in Patients Diagnosed With COVID-19.
    Am J Gastroenterol. 2021;116.
    PubMed    


  63. SIGRID Y, Scott S, Shannon C
    P024 Anorectal Manometry in Patients with Fecal Incontinence After Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease: A Cohort Study.
    Am J Gastroenterol. 2021;116.
    PubMed    


  64. KEVIN C, Sandra K, Noll R
    P023 Parental Distress in Pediatric Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed    


  65. VARUN J, Brian B, Esteban F
    P022 Biologic Therapy and Therapeutic Drug Monitoring in Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  66. VITOR MS, Tiago LC, Marta F, Tiago CG, et al
    P020 Proton Pump Inhibitor Therapy: Providing "Acid" Outcomes in Patients With Inflammatory Bowel Disease Under Infliximab Treatment.
    Am J Gastroenterol. 2021;116.
    PubMed    


  67. IANA G, Randall J, Marc P
    P019 Not All Fecal Calprotectin is Specific for Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed    


  68. MARIYA Z, Oleg K, Karina N
    P017 Increased Level of Immunoglobulin G in the Development of Adverse Reactions in Patients With Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  69. RICHARD WY
    P011 Prevalence of Cannabis Use Disorder in Inflammatory Bowel Disease Hospitalizations in the United States and Effect on Length of Stay.
    Am J Gastroenterol. 2021;116.
    PubMed    


  70. HARTMAN B, Diana H, Casey C
    P009 Assessing the Status Quo: Ulcerative Colitis Monitoring in a Community GI Practice.
    Am J Gastroenterol. 2021;116.
    PubMed    


  71. OLEG K, Sergey K, Anna K, Albina L, et al
    P006 The Relationship of Histological Remission With the Duration of the Anamnesis Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  72. OLEG K, Anna K, Albina L, Anait B, et al
    P004 Steroid-Free Remission in Patients With Ulcerative Colitis Receiving Tofacitinib in Real Clinical Practice.
    Am J Gastroenterol. 2021;116.
    PubMed    


  73. HUI C, Tian F, Lintao D, Xuejie C, et al
    P003 Meat Consumption and All-Cause Mortality in 5763 Inflammatory Bowel Disease Patients: A Prospective Cohort Study.
    Am J Gastroenterol. 2021;116.
    PubMed    


  74. STONE M, Morrison M, Forster E
    P076 The Role of Dual Biologic Therapy in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  75. SNINSKY J, Barnes E, Zhang X, Long M, et al
    P075 Urgency and its Association with Quality of Life and Clinical Outcomes in Ulcerative Colitis Patients.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  76. DALAL R, Mitri J, Goodrick H, Allegretti J, et al
    P074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naive Patients With Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  77. SAHN B, Pascuma K, Tracey K, Markowitz J, et al
    P072 Non-invasive Vagal Nerve Stimulation to Treat Crohn Disease and Ulcerative Colitis in Children and Young Adults: A Proof-of-Concept Clinical Trial.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  78. ROMERO LJ, Gomez JL, Espinosa TC, Trujillo de la Fuente K, et al
    P063 Prevalence in the Use of Complementary/Alternative Medicine in Patients With Inflammatory Bowel Disease from Centro Medico Nacional 20 de Noviembre.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  79. TRUJILLO DE LA FUENTE K, Lopez Gomez J, Cortes Espinosa T, Perez-Cabeza de Vaca R, et al
    P061 Impact of Inflammatory Bowel Disease on sleep quality in a Mexican population attended in a referral center.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  80. PARRA IZQUIERDO V, Gutierrez J, Florez C, Jaimes D, et al
    P060 Screening Criteria of Inflammatory Bowel Disease: Application in Colombian Patients With Spondyloarthritis.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  81. PAREDES AMENABAR C, Cortes Espinosa T, Lopez Gomez J, Trujillo de la Fuente K, et al
    P057 How Distance Between Residence and Treatment Center Impact the Outcome of Patients With Inflammatory Bowel Disease at CMN 20.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  82. PARRA IZQUIERDO V, Frias-Ordonez J, Galindo P, Romero-Sanchez C, et al
    P056 Real life experience with the use of tofacitinib in ulcerative colitis in Colombia: case series.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  83. TSE CS, Andrea S, Elfanagely Y, Tanzer J, et al
    P055 Sociodemographic Differences in Fecal Enteropathogen Testing Patterns in Adults Hospitalized for Inflammatory Bowel Disease Flares.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  84. FARIA M, Sassaki L, Andrade A, Kaiser Junior R, et al
    P052 National Registration of Patients With Inflammatory Bowel Disease in Brazil on Behalf of GEDIIB.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  85. FREITAS M, Capela TL, Macedo Silva V, Arieira C, et al
    P051 Identifying High-Risk Patients With Acute Severe Ulcerative Colitis: Is the ACE Index Useful?
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  86. PARRA IZQUIERDO V, Chumacero K, Alvarado J, Buenahora M, et al
    P050 Oral Inflammatory Changes Associated With Inflammatory Bowel Disease in Spondyloarthritis Associated With Early Endoscopic Findings.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  87. SHINTAKU D, Lopes M, de Oliveira AC, Beraldo R, et al
    P049 Investigation of Liver Diseases by Ultrasound in Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  88. LOPES M, Shintaku D, de Oliveira AC, Beraldo R, et al
    P045 Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD) in a Brazilian public healthcare clinic.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  89. CAI Q, Sanon M, Batyrbekova N, Di Scala L, et al
    P043 Resource Utilization and Productivity Loss among Patients with Inflammatory Bowel Disease in Sweden: A Longitudinal Nationwide Population-based Study.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  90. LONG M, Cross R, Calkwood J, Pondel M, et al
    P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  91. COLOMBEL JF, D'Haens G, Irving P, Petersen A, et al
    P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  92. HUDESMAN D, Long M, Wolf D, Hanauer S, et al
    P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  93. SANDS B, Pondel M, Silver M, Petersen A, et al
    P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  94. RUBIN D, Panaccione R, Potts Bleakman A, Kayhan C, et al
    P028 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Patient and Healthcare Professional Perspectives on Experience of Ulcerative Colitis Symptoms.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  95. DADLANI A, Gala K, Rai J, Rai S, et al
    P027 Brain Fog in Patients With Inflammatory Bowel Disease, and Association With Use of Probiotics.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  96. YOUNG S, Smukalla S, Chang S
    P024 Anorectal Manometry in Patients with Fecal Incontinence After Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease: A Cohort Study.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  97. CESA K, Kim S, Robert N
    P023 Parental Distress in Pediatric Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  98. JAIN V, Behm B, Figueroa E
    P022 Biologic Therapy and Therapeutic Drug Monitoring in Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  99. MACEDO SILVA V, Lima Capela T, Freitas M, Curdia Goncalves T, et al
    P020 Proton Pump Inhibitor Therapy: Providing "Acid" Outcomes in Patients With Inflammatory Bowel Disease Under Infliximab Treatment.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  100. GUEORGUIEVA I, Jacobs R, Piper M
    P019 Not All Fecal Calprotectin is Specific for Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  101. ZVYAGLOVA M, Knyazev O, Noscova K
    P017 Increased Level of Immunoglobulin G in the Development of Adverse Reactions in Patients With Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  102. WANG YR
    P011 Prevalence of Cannabis Use Disorder in Inflammatory Bowel Disease Hospitalizations in the United States and Effect on Length of Stay.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  103. BRUNT H, Hamer D, Chapman C
    P009 Assessing the Status Quo: Ulcerative Colitis Monitoring in a Community GI Practice.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  104. KNYAZEV O, Khomeriki S, Kagramanova A, Lishchinskaya A, et al
    P006 The Relationship of Histological Remission With the Duration of the Anamnesis Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  105. KNYAZEV O, Kagramanova A, Lishchinskaya A, Babayan A, et al
    P004 Steroid-Free Remission in Patients With Ulcerative Colitis Receiving Tofacitinib in Real Clinical Practice.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  106. CHEN H, Fu T, Dan L, Chen X, et al
    P003 Meat Consumption and All-Cause Mortality in 5763 Inflammatory Bowel Disease Patients: A Prospective Cohort Study.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  107. DAI C, Jiang M, Huang YH
    The Association Between Serum Infliximab Concentrations and Clinical Outcomes in Fistulizing Crohn's Disease.
    Am J Gastroenterol. 2021;116:2481-2482.
    PubMed    


    November 2021
  108. MELMED GY, Oliver B, Hou JK, Lum D, et al
    Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 Nov 19. pii: 00000434-990000000-00153.
    PubMed     Abstract available


  109. CALDERA F, Knutson KL, Saha S, Wald A, et al
    Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls.
    Am J Gastroenterol. 2021 Nov 18. pii: 00000434-990000000-00148.
    PubMed     Abstract available


  110. BRUNT H, Chapman JC
    The Inflammatory Bowel Disease-Focused Primary Care Provider: An Addition to the IBD Specialty Medical Home.
    Am J Gastroenterol. 2021 Nov 17. pii: 00000434-990000000-00144.
    PubMed    


  111. NGUYEN NH, Martinez I, Atreja A, Sitapati AM, et al
    Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review.
    Am J Gastroenterol. 2021 Nov 9. pii: 00000434-990000000-00141.
    PubMed     Abstract available


  112. ALMARIO CV, Kogan L, van Deen WK, Scott FI, et al
    Health Economic Impact of a Multicenter Quality-of-Care Initiative for Reducing Unplanned Healthcare Utilization Among Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 Nov 3. pii: 00000434-990000000-00133.
    PubMed     Abstract available


  113. CHO JM, Loftus EV Jr, Bruining DH, Chedid VG, et al
    Vulvar Crohn's Disease: Clinical Features and Outcomes.
    Am J Gastroenterol. 2021;116:2296-2299.
    PubMed     Abstract available


    October 2021
  114. LAUBE R, Tran Y, Paramsothy S, Leong RW, et al
    Assisted Reproductive Technology in Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2021 Oct 25. pii: 00000434-990000000-00131.
    PubMed     Abstract available


  115. THAKUR K, Barrett TA
    Social Determinants of Health in Inflammatory Bowel Diseases: Barriers and Opportunities.
    Am J Gastroenterol. 2021;116:2146.
    PubMed    


  116. ASHHAB AA, Lee M, Melmed GY
    Extensive Upper Gastrointestinal Fistulization in Crohn's Disease, an Uncommon Cause for a Common Presentation.
    Am J Gastroenterol. 2021;116:1978.
    PubMed    


    September 2021
  117. BATTAT R, Long MD
    Is Proactive Therapeutic Drug Monitoring Ready for the Spotlight in Inflammatory Bowel Disease? Follow the Data.
    Am J Gastroenterol. 2021 Sep 13. pii: 00000434-990000000-00100.
    PubMed     Abstract available


    August 2021
  118. SANGHA M, Roitman I, Sultan K, Swaminath A, et al
    SARS-CoV-2 Immunization in Patients With Inflammatory Bowel Disease May Result in Disease Flares.
    Am J Gastroenterol. 2021 Aug 18. pii: 00000434-990000000-00081.
    PubMed    


  119. CHEIFETZ AS, Abreu MT, Afif W, Cross RK, et al
    A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 Aug 13. pii: 00000434-990000000-00067.
    PubMed     Abstract available


  120. RICCIUTO A, Carman N, Benchimol EI, Siddiqui I, et al
    Prospective Evaluation of Endoscopic and Histologic Indices in Pediatric Ulcerative Colitis Using Centralized Review.
    Am J Gastroenterol. 2021 Aug 13. pii: 00000434-990000000-00066.
    PubMed     Abstract available


  121. DULAI PS, Jairath V, Narula N, Wong E, et al
    A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease.
    Am J Gastroenterol. 2021;116:1709-1719.
    PubMed     Abstract available


    July 2021
  122. HARRISON N, Humes R, Singla M
    Skip, Stop, Switch, and Spare: Steroid Therapy in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 Jul 19. pii: 00000434-990000000-00049.
    PubMed    


  123. SCHUMANN M, Sonnenberg E, Siegmund B, Meier K, et al
    A 39-Year-Old Man With Crohn's Disease and a Unclear Rash on His Left Cheek.
    Am J Gastroenterol. 2021;116:1374.
    PubMed    


    June 2021
  124. ABDALLA MI, Levesque BG
    Progress in Corticosteroid Use in the Era of Biologics With Room for Improvement.
    Am J Gastroenterol. 2021;116:1187-1188.
    PubMed     Abstract available


  125. TARGOWNIK LE, Bernstein CN, Benchimol EI, Kaplan GG, et al
    Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis.
    Am J Gastroenterol. 2021;116:1284-1293.
    PubMed     Abstract available


    May 2021
  126. DE GIORGI V, Trane L, Silvestri F, Venturi F, et al
    Pyodermatitis-Pyostomatitis Vegetans in Active Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 May 31. pii: 00000434-900000000-98762.
    PubMed    


  127. BOTWIN GJ, Li D, Figueiredo J, Cheng S, et al
    Adverse Events Following SARS-CoV-2 mRNA Vaccination: Among Patients with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 May 25. pii: 00000434-900000000-98766.
    PubMed     Abstract available


  128. TEICH N, Stallmach A, Bruns T
    Greenspace in Childhood: A New Avenue to Prevent Inflammatory Bowel Disease?
    Am J Gastroenterol. 2021 May 7. pii: 00000434-900000000-98784.
    PubMed    


  129. TANG J, Huang Z, Guo H, Ding N, et al
    Online Video Clinic Satisfies the Medical Requirements of Patients with IBD During the COVID-19 Outbreak.
    Am J Gastroenterol. 2021;116:1087.
    PubMed    


  130. PAPAMICHAEL K, Vande Casteele N, Jeyarajah J, Jairath V, et al
    Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis.
    Am J Gastroenterol. 2021;116:1007-1014.
    PubMed     Abstract available


    April 2021
  131. KHAN N, Patel D, Xie D, Pernes T, et al
    Are Patients With Inflammatory Bowel Disease at an Increased Risk of Developing SARS-CoV-2 than Patients Without Inflammatory Bowel Disease? Results From a Nationwide Veterans' Affairs Cohort Study.
    Am J Gastroenterol. 2021;116:808-810.
    PubMed     Abstract available


  132. KHAN N, Patel D, Trivedi C, Kavani H, et al
    Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients With Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk.
    Am J Gastroenterol. 2021;116:741-747.
    PubMed     Abstract available


  133. SONNENBERG A
    Do Forgotten Symptoms Need Treatment?
    Am J Gastroenterol. 2021;116:841-842.
    PubMed    


  134. HA C
    The Age-Old Conundrum With Thiopurines: Are the Accumulating Risks Greater Than Benefits?
    Am J Gastroenterol. 2021;116:671-672.
    PubMed     Abstract available


    March 2021
  135. BERNSTEIN CN, Nugent Z, Singh H
    Persistently High Rate of Venous Thromboembolic Disease in Inflammatory Bowel Disease: A Population-Based Study.
    Am J Gastroenterol. 2021 Mar 24. pii: 00000434-900000000-98845.
    PubMed     Abstract available


  136. SLATER NR, Loomes DE
    Endoscopic Vacuum-Assisted Wound Closure of a Rectal Perforation in the Setting of Active Ulcerative Colitis.
    Am J Gastroenterol. 2021 Mar 2. pii: 00000434-900000000-98819.
    PubMed    


    January 2021
  137. COELHO-PRABHU N, Kane S
    Does Size Really Matter?
    Am J Gastroenterol. 2021;116:84-85.
    PubMed     Abstract available


  138. HAMMOUDI N, Allez M
    Response to Hanzel.
    Am J Gastroenterol. 2021;116:218.
    PubMed    


  139. HANZEL J
    A Novel Endoscopic Score for Postoperative Recurrence of Crohn's Disease: More Information Needed.
    Am J Gastroenterol. 2021;116:217-218.
    PubMed    


  140. RIVIERE P, D'Haens G, Peyrin-Biroulet L, Baert F, et al
    Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX.
    Am J Gastroenterol. 2021;116:134-141.
    PubMed     Abstract available


    December 2020
  141. LACY BE, Pimentel M, Brenner DM, Chey WD, et al
    ACG Clinical Guideline: Management of Irritable Bowel Syndrome.
    Am J Gastroenterol. 2020 Dec 14. doi: 10.14309/ajg.0000000000001036.
    PubMed     Abstract available


  142. KORELITZ BI, Sachar DB, Schneider J
    Full Potential of 6-Mercaptopurine in IBD May Remain Untapped.
    Am J Gastroenterol. 2020;115:2109-2110.
    PubMed    


  143. FERNANDA F, Mirella O, Danielle F, Pedro G, et al
    P074 Prevalence and Associated Factors With Non-Adherence to Maintenance Therapy for Ulcerative Colitis in Deep Remission.
    Am J Gastroenterol. 2020;115.
    PubMed    


  144. PRADEEP KR, Deloshaan S, Dheeraj S, Hadi M, et al
    P070 Outcomes of Acute Severe Ulcerative Colitis in Older Adults.
    Am J Gastroenterol. 2020;115.
    PubMed    


  145. DELOSHAAN S, Pradeep KR, Dheeraj S, Hadi M, et al
    P069 Admission Steroid Use, Serum Albumin and Endoscopic Severity Predict Intravenous Steroid Failure in Patients With Acute Severe Ulcerative Colitis.
    Am J Gastroenterol. 2020;115.
    PubMed    


  146. JAQUELINE B, Juliana C, Dos Santos B, Caroline D, et al
    P068 Therapeutic Aspects in Pediatric Inflammatory Bowel Disease - A Multi-Centric Study From Brazil.
    Am J Gastroenterol. 2020;115.
    PubMed    


  147. FLAVIA P, Cyrla Z, de Souza H, Jessica M, et al
    P066 Hospitalization and Surgery Rates in Patients With Inflammatory Bowel Disease in Brazil: A Time-Trend Analysis.
    Am J Gastroenterol. 2020;115.
    PubMed    


  148. JENNIFER MO, Megan L, Jean A
    P065 Inflammatory Bowel Disease or Bowel Endometriosis? Two Cases of Large Bowel Obstruction.
    Am J Gastroenterol. 2020;115.
    PubMed    


  149. JAQUELINE B, Juliana C, Dos Santos Beatriz, Caroline D, et al
    P064 Clinical Aspects of Pediatric Inflammatory Bowel Disease - A Multicentric Study From Brazil.
    Am J Gastroenterol. 2020;115.
    PubMed    


  150. FABIANA B, Cesar A, Marcio C, Carolina M, et al
    P061 Prophylaxis of Hepatitis B Reactivation and Inflammatory Bowel Disease: A case report.
    Am J Gastroenterol. 2020;115.
    PubMed    


  151. SVETLANA L, Morris G, Vasiliki S
    P056 Power Calculations in Randomised Controlled Trials of Inflammatory Bowel Disease.
    Am J Gastroenterol. 2020;115.
    PubMed    


  152. WALAA M, Hisham W, Walid H, Fadi F, et al
    P049 Should the Gallbladder be Empirically Removed at Time of Intestinal Resection in Inflammatory Bowel Disease Patients?
    Am J Gastroenterol. 2020;115.
    PubMed    


  153. ERIC J
    P047 Awareness and Impact of Recent AGA Guideline Changes for Moderate to Severe Ulcerative Colitis Patients.
    Am J Gastroenterol. 2020;115.
    PubMed    


  154. ERIC J
    P046 Though Biosimilar Infliximab Prescribing in Inflammatory Bowel Disease Has Increased, Branded Infliximab Continues to Be Prescribed More Often.
    Am J Gastroenterol. 2020;115.
    PubMed    


  155. CASEY C, Jenny G, Michelle B, Joe L, et al
    P042 The CONCERT Initiative: Impact of Inflammatory Bowel Disease Care Referral Pathway.
    Am J Gastroenterol. 2020;115.
    PubMed    


  156. SARA L, Millie L, Uma M
    P040 Indications for Cesarean Section in Pregnant Women with Inflammatory Bowel Disease: Results from the PIANO Registry.
    Am J Gastroenterol. 2020;115.
    PubMed    


  157. SARA H, David H, Joe Z, Ryan H, et al
    P038 Factors Associated with Impaired Patient-Reported Outcomes and Work Productivity Among Patients with Ulcerative Colitis in Remission.
    Am J Gastroenterol. 2020;115.
    PubMed    


  158. DAVID P, Caterina O, Christopher A, Gregory AC, et al
    P037 Efficacy and Safety of 1-L NER1006 Bowel Preparation in Patients with Inflammatory Bowel Disease: Analysis of 2 Phase 3 Studies.
    Am J Gastroenterol. 2020;115.
    PubMed    


  159. CLARA U, Amanda T, Debora T, Giovana C, et al
    P036 Clinical and Psychological Factors Associated with Impaired Body Image in Patients with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2020;115.
    PubMed    


  160. KAUSTAV S, Austin T, Roman G, Allison M, et al
    P033 Demographic Factors Associated with Successful Telehealth Visits in Inflammatory Bowel Disease Patients.
    Am J Gastroenterol. 2020;115.
    PubMed    


  161. WILLIAM S, Brian F, Stephen H, Severine V, et al
    P031 Ozanimod in Patients with Moderate-to-Severe Ulcerative Colitis: Long-Term Safety and Efficacy from the Phase 2 TOUCHSTONE Study 4-Year Open-Label Extension.
    Am J Gastroenterol. 2020;115.
    PubMed    


  162. SILVIO D, Brian F, Stephen H, Igor J, et al
    P030 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Maintenance in the Phase 3 True North Study.
    Am J Gastroenterol. 2020;115.
    PubMed    


  163. EDWARD B, Harris A, Joe Z, Antoine S, et al
    P027 Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD.
    Am J Gastroenterol. 2020;115.
    PubMed    


  164. SHINTARO A, Jacob O, Cindy T, Victoria R, et al
    P026 Assessment of Contributing Factors for Fistula Development in Patients with Inflammatory Bowel Disease Treated by Proctocolectomy with Ileal Pouch-Anal Anastomosis.
    Am J Gastroenterol. 2020;115.
    PubMed    


  165. WILLIAM S, Geert D, Doug W, Stephen H, et al
    P025 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Induction in the Phase 3 True North Study.
    Am J Gastroenterol. 2020;115.
    PubMed    


  166. GALIYA B, Alisa R, Maria L
    P024 Medical Decision Support System in the Diagnosis of Ulcerative Colitis.
    Am J Gastroenterol. 2020;115.
    PubMed    


  167. MICHAEL C, Puza S, Benjamin C, Leonardo S, et al
    P021 Characteristics of Patients Treated with Tofacitinib for Ulcerative Colitis in the Real World: Findings from a Large US Claims Database.
    Am J Gastroenterol. 2020;115.
    PubMed    


  168. SUBRATA G, Geert D, Vipul J, Florian R, et al
    P012 Ozanimod Reduced Fecal Calprotectin Levels in Patients with Ulcerative Colitis in the Phase 3 True North Study.
    Am J Gastroenterol. 2020;115.
    PubMed    


  169. ROGERIO P, Julio C, Liliana C, Erika B, et al
    P008 Long-Term Effectiveness and Safety of Ustekinumab for The Treatment of Crohn s Disease: A Brazilian Multicentre Real-world Study.
    Am J Gastroenterol. 2020;115.
    PubMed    


  170. OLEG K, Albina L, Anatoliy K, Anna K, et al
    P005 Overcoming Secondary Loss of Response to Infliximab in Patients With Ulcerative Colitis With the Use of Mesenchymal Stromal Cells.
    Am J Gastroenterol. 2020;115.
    PubMed    


  171. OLEG K, Anna K, Albina L, Tatyana S, et al
    P002 Frequency and Causes of Prolongation of the Induction Course of Tofacitinib in Patients with Ulcerative Colitis.
    Am J Gastroenterol. 2020;115.
    PubMed    


  172. ERNESTO R, Rachel H, Meera L, Pablo P, et al
    P001 North-South Gradient in the Incidence of Pediatric Inflammatory Bowel Disease Along the Atlantic Coast.
    Am J Gastroenterol. 2020;115.
    PubMed    


    November 2020
  173. KHAN N, Patel D, Trivedi C, Kavani H, et al
    Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients With Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk.
    Am J Gastroenterol. 2020 Nov 26. doi: 10.14309/ajg.0000000000001058.
    PubMed     Abstract available


  174. ZAVER HB, Ghoz H, Azar A, Alexander LF, et al
    Inferior Mesenteric Arteriovenous Malformation Masquerading as Ulcerative Colitis.
    Am J Gastroenterol. 2020 Nov 10. doi: 10.14309/ajg.0000000000000917.
    PubMed    


  175. CHAPARRO M, Gordillo J, Domenech E, Esteve M, et al
    Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial.
    Am J Gastroenterol. 2020;115:1802-1811.
    PubMed     Abstract available


  176. BANTY A, Melmed GY
    Improving Hepatitis B Virus Vaccination Responses in Inflammatory Bowel Disease: Does Greater Dose and Greater Frequency Lead to Greater Protection?
    Am J Gastroenterol. 2020;115:1797-1798.
    PubMed     Abstract available


  177. LITTLE DHW, Tabatabavakili S, Shaffer SR, Nguyen GC, et al
    Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease: A Systematic Review.
    Am J Gastroenterol. 2020;115:1768-1774.
    PubMed     Abstract available


  178. WINDSOR JW, Underwood FE, Brenner E, Colombel JF, et al
    Data Visualization in the Era of COVID-19: An Interactive Map of the SECURE-IBD Registry.
    Am J Gastroenterol. 2020;115:1923-1924.
    PubMed    


  179. CHAPUIS-BIRON C, Kirchgesner J, Pariente B, Bouhnik Y, et al
    Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID.
    Am J Gastroenterol. 2020;115:1812-1820.
    PubMed     Abstract available


    October 2020
  180. BUCHNER AM, Schneider Y, Lichtenstein GR
    Biosimilars in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2020 Oct 27. doi: 10.14309/ajg.0000000000000844.
    PubMed     Abstract available


  181. GUBATAN J, Nielsen OH, Levitte S, Juhl CB, et al
    Biologics During Pregnancy in Women With Inflammatory Bowel Disease and Risk of Infantile Infections: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2020 Oct 23. doi: 10.14309/ajg.0000000000000910.
    PubMed     Abstract available


  182. KHAN N, Patel D, Xie D, Pernes T, et al
    Are Patients With Inflammatory Bowel Disease at an Increased Risk of Developing SARS-CoV-2 than Patients Without Inflammatory Bowel Disease? Results From a Nationwide Veterans' Affairs Cohort Study.
    Am J Gastroenterol. 2020 Oct 19. doi: 10.14309/ajg.0000000000001012.
    PubMed     Abstract available


  183. ELTEN M, Benchimol EI, Fell DB, Kuenzig ME, et al
    Residential Greenspace in Childhood Reduces Risk of Pediatric Inflammatory Bowel Disease: A Population-Based Cohort Study.
    Am J Gastroenterol. 2020 Oct 8. doi: 10.14309/ajg.0000000000000990.
    PubMed     Abstract available


  184. FIORINO G, Gilardi D, Radice S, Furfaro F, et al
    Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures.
    Am J Gastroenterol. 2020;115:1719-1721.
    PubMed     Abstract available


  185. MANSOOR E, Khoudari G, Abou Saleh M, Elfadawy N, et al
    The Many Faces of COVID-19: Atypical Presentation of COVID-19 in a Patient With Crohn's Disease With Acute Diarrhea Leading to Severe Hypovolemic Hyponatremia-A Case Report.
    Am J Gastroenterol. 2020;115:1730-1731.
    PubMed    


  186. GIESE-KIM N, Wu M, Dehghan M, Sceats LA, et al
    Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2020;115:1698-1706.
    PubMed     Abstract available


    September 2020
  187. CHAPARRO M, Gordillo J, Domenech E, Esteve M, et al
    Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial.
    Am J Gastroenterol. 2020 Sep 30. doi: 10.14309/ajg.0000000000000926.
    PubMed     Abstract available


  188. BANTY A, Melmed GY
    Improving Hepatitis B Virus Vaccination Responses in Inflammatory Bowel Disease: Does Greater Dose and Greater Frequency Lead to Greater Protection?
    Am J Gastroenterol. 2020 Sep 25. doi: 10.14309/ajg.0000000000000921.
    PubMed     Abstract available


  189. DALAL RS, Palchaudhuri S, Snider CK, Gitelman Y, et al
    A Multimodal Intervention Using Nonopioid Analgesics Is Associated With Reduced Intravenous Opioid Exposure Among Hospitalized Patients With Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2020;115:1474-1485.
    PubMed     Abstract available


  190. QUINN KP, Raffals LE
    An Update on the Medical Management of Inflammatory Pouch Complications.
    Am J Gastroenterol. 2020;115:1439-1450.
    PubMed     Abstract available


    August 2020
  191. NARULA N, Wong ECL, Aruljothy A, Dulai PS, et al
    Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial.
    Am J Gastroenterol. 2020;115:1236-1245.
    PubMed     Abstract available


    July 2020
  192. HAMMOUDI N, Auzolle C, Tran Minh ML, Boschetti G, et al
    Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's Disease.
    Am J Gastroenterol. 2020;115:1084-1093.
    PubMed     Abstract available


    June 2020
  193. ROZICH JJ, Holmer A, Singh S
    Effect of Lifestyle Factors on Outcomes in Patients With Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2020;115:832-840.
    PubMed     Abstract available


    May 2020
  194. BEWTRA M, Lichtenstein GR
    Mongersen and SMAD-7 Inhibition, Not a Lucky 7 for Patients With IBD: When Trial Design Is as Important as Disease Therapy.
    Am J Gastroenterol. 2020;115:687-688.
    PubMed     Abstract available


  195. LEE MW, Pourmorady JS, Laine L
    Use of Fecal Occult Blood Testing as a Diagnostic Tool for Clinical Indications: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2020;115:662-670.
    PubMed     Abstract available


    March 2020
  196. SHAH A, Macdonald GA, Morrison M, Holtmann G, et al
    Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework.
    Am J Gastroenterol. 2020 Mar 25. doi: 10.14309/ajg.0000000000000604.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: